Techdow USA Announces FDA Approval of Generic Lovenox in Prefilled Syringes

U.S. Food and Drug Administration© ANA BARAULIA / Getty Images / Canva

LANGHORNE, PA — Techdow USA Inc. this week announced the FDA approval of Enoxaparin Sodium (Preservative Free) in Prefilled Syringes for the U.S. market.

“Techdow USA is excited to bring this critical product to institutions, retail and other networks in need of a safe, affordable and reliable source of Enoxaparin,” said Darren Alkins, Chief Executive Officer of Techdow USA. “As a vertically integrated company in this complex environment with difficult to source raw material and state-of-the-art prefilled syringe manufacturing, our U.S. and global networks will help ensure reliable Enoxaparin supply, while offering competitive pricing. Techdow USA will be a long-term reliable resource to the marketplace.”

The launch of Enoxaparin will complement Techdow USA’s existing Heparin Sodium injection business, which was successfully launched in 2022.

Enoxaparin Sodium (Preservative Free) Prefilled Syringes had US brand and generic sales of approximately $550 million, according to IQVIA Health for the 12 months ending December 2022.

For more information, visit

To report SUSPECTED ADVERSE REACTIONS, contact Hepalink USA, Inc./Techdow USA, Inc. at 1-888-355-1375 or FDA at 1-800-FDA-1088 or

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News.

READ:  QNB Corp. Declares Q2 2023 Dividend